key: cord-0700934-3t9wfem1 authors: Rahnama, Shadi; Irani, Maryam Azimzadeh; Amininasab, Mehriar; Ejtehadi, Mohammad Reza title: S494 O-glycosylation site on the SARS-COV-2 RBD Affects the Virus Affinity to ACE2 and its Infectivity; A Molecular Dynamics Study date: 2020-11-29 journal: bioRxiv DOI: 10.1101/2020.09.12.294504 sha: b64edfab1ea1cc200f19446e342692dc3ee898a5 doc_id: 700934 cord_uid: 3t9wfem1 SARS-COV-2 is a strain of Coronavirus family which caused the extensive pandemic of COVID-19, which is still going on. Several studies showed that the glycosylation of virus spike (S) protein and the Angiotensin-Converting Enzyme 2 (ACE2) receptor on the host cell is critical for the virus infectivity. Molecular Dynamics (MD) simulations were used to explore the role of a novel mutated O-glycosylation site (D494S) on the Receptor Binding Domain (RBD) of S protein. This site was suggested as a key mediator of virus-host interaction. We showed that the decoration of S494 with elongated O-glycans results in stabilized interactions on the direct RBD-ACE2 interface with more favorable binding free energies for longer oligosaccharides. Hence, this crucial factor must be taken into account for any further inhibitory approaches towards RBD-ACE2 interaction. The SARS-COV-2 virion assembly and its infusion into the human cell are similar to the one known for SARS-COV. 2 The fusion protein known as the spike (S) protein interacts with ACE2 on the host cell via its Receptor Binding Domain (RBD) 3, 7 (Figure 1 ).The RBD-ACE2 interaction takes place via four β strands on RBD (β4-β7) and two α helices on ACE2 binding interface (H1,H2) 3 ( Figure 1 ). Electron microscopy and X-ray crystal structures elucidated the active form of SARS-COV-2 S protein which assembles as a trimer, 2 and one RBD of one S protein complex ACE2, 3 respectively. The structures of S protein in the apo and ACE2 bound complexes show that RBD adopts a 3D fold similar to the RBD of SARS-COV;. 2 However, six novel mutations on SARS-COV-2 RBD could lead to different binding affinity to ACE2. 1 Speculations regarding SARS-COV-2-ACE2 binding affinity suggested two different scenarios. One reported a dramatic increase (up to 20-fold) in the binding affinity of SARS-COV-2 to ACE2 compared to SARS-COV. 2 While, the other suggests a similar binding affinity for SARS-COV-2 and SARS-COV to ACE2. 3, 8 Either way, the mutations in SARS-COV2 RBD certainly results in attenuated binding affinity of all designed inhibitors which successfully work on SARS-COV. 2 It was a challenging issue for anti-SARS-COV-2 drug design attempts since the pandemic has started. Figure 1 : The extracellular domain of human ACE2 and RBD of SARS-COV-2 S protein is shown with gray and purple, respectively (A and B). The RBD attached O-glycan is shown with green spheres (C). For the sake of simplicity, only the N-glycans in the proximity of RBD-ACE2 interface are shown with pink spheres. Visualization of the complex with full presentation of the N-glycans can be found in Figure 11 (D). Two O-glycan interaction sites H1 and H2, are shown with orange (E). In addition to the 3D structures of RBD-ACE2 complex, several recent Molecular Dynamics (MD) studies addressed the complex dynamics to design peptide inhibitors. That block the ACE2-RBD interaction and evaluate the currently targeted binding epitopes' accessibility for further improvements. 4, 9, 10 Earlier MD studies explored the effect of pH 11 and temperature 12 on the dynamics of SARS-COV-ACE2 complex.To the best of our knowledge, there is currently no approved therapeutic inhibitor for SARS-COV-2. A pioneering study showed that the observed mutations at the junction of S1 and S2 subdomains of the SARS-COV-2 S protein result in the emergence of a polybasic cleavage site adjacent to three O-glycosylation sites which are novel to SARS-COV-2 and were not observed in any other related virion. 1 It was proposed that O-glycosylation (addition of glycan building blocks to hydroxyl oxygen of Ser/Thr residues which is an enzymatic post transnational modification 13 ) could lead to recognition of polybasic cleavage site by Furin enzyme and thus resulted in higher infectivity and broadens the host range of the virus. 1 A Recent comprehensive experimental mass-spectrometry study on both N-and Oglycans attached to the spike protein did not report O-glycosylation of the S494. However, two O-glycosylated sites (S325/T323) were reported on the RBD. 14 Another recent computational study that was validated by experimental data reported that the S325/T323 O-glycosylation sites that were observed by Shajahan et al. is present with 11% frequency along side other O-glycosylation site that were decorated with lower frequencies. 15 Six mutations have been reported on the RBD of SARS-COV-2 compared to the SARS-COV. One of these six occurring mutations is D494S on the RBD of S protein. Based on the proposed mechanism for the O-glycosylation of Furin cleavage site and the Evidences mentioned above, 1, 14, 15 we propose that Serine494 of SARS-COV-2 RBD could also become O-glycosylated even though it is not experimentally confirmed ( Figure 1 Putting all the information mentioned above together, it is highly plausible that D494S mutation has an evolutionary origin and leads to O-glycosylation of RBD in the SARS-COV-2. Hence, the O-glycosylation could be the overlooked factor for the SARS-COV-2 increased binding affinity to ACE2, explaining the virus's high infectivity in the human host and exposing people with a higher level of blood sugar at higher risk. 24 Our observations may explain the reason for the higher vulnerability of diabetic patients to infection. Herein, we explored this possibility by modeling the O-glycosylated RBD structure and dynamics in interaction with ACE2 ( Figure 2 ). We show that O-glycosylation does indeed increase SARS-COV-2 RBD-ACE2 binding affinity. Also, we show that attachment of the elongated O-glycans will increase the binding affinity. Furthermore, we also considered the structural role of N-glycosylation (addition of glycan building blocks to the nitrogen atom of Asn located at the Asn-X-Ser/Thr motif, enzymatic post-translationalmodification) of both RBD and ACE2 in all of the simulations. In summary, this work provides strong evidence that O-glycosylation of SARS-COV2 RBD in the respiratory airways leads to stronger interactions between the virion and the host cell receptor. Hence, further inhibitor design attempts must take the detailed atomistic glycan-protein interaction reported here into account as a critical factor for future investigations. The crystal structure of SARS-COV-2 RBD (residue 333 to 526) in complex with the extracellular domain of ACE2 (residue 19 to 615) (PDB ID: 6M0J) was used as the starting structure. Zn 2+ and Cl − ions which were resolved in the crystal structure for their crucial role in stabilizing ACE2 structure were also preserved at S1 and S2 subunits of ACE2. All Aspargines located within N-glycosylation motifs from RBD (Asn343) and ACE2 (Asn53, Asn90, Asn103, Asn322, Asn432, and Asn546) were glycosylated. The GLYCAM online builder 25 was used to attach the oligosaccharide glycans to each site. This oligosaccharide model was selected as a primary model of glycosylation which occurs in normal human cells. 26 Supporting table 1 provides details on the structure of attached N-glycans. O-glycosylation of Serine494 of RBD was carried out by attaching three models of core and branched typical human O-glycans using GLYCAM online builder. 25 Models I, II, and III are consist of two, five, and six monosaccharide units, respectively ( Figure 2 ). These O-glycan models were attached to RBD, while RBD-ACE2 complex was kept fully Nglycosylated ( Figure 1 ). The RBD-ACE2 model without attached O-glycan will be referred to as model 0 in the rest of the text and figures. All systems were solvated using TIP3P water model 27 and were neutralized by attaining a buffered environment in 150 mM NaCl. The resulting water box approximately has a dimension of 121 × 111 × 149Å 3 and are typically consist of 190000 atoms each. All systems were parameterized with the CHARMM36m force field, 28,29 and NAMD2.12 30 was used to perform the MD simulations. Periodic boundary conditions under NPT ensemble was applied, while employing Langevin thermostat and Nose-Hoover Langevin piston method to keep systems' temperature and pressure at 310 K and 1 bar, respectively. A cutoff ofÅ was assigned for computation of short range nonbonded van der Waals interactions. The particle mesh Ewald method 31 was used for long-range electrostatic interactions. R-RESPA multiple time-step schemes were used for the integration of motion equations. 30 Using this integrator, the Lennard-Jones interactions and bonded ones were updated every step and electrostatic interactions every two steps. Along with the restraining of all covalent hydrogen bonds by SHAKE, the time steps for integration were set to 2fs. Final models of all complexes were minimized for 5000 steps to remove any steric clashes. Following minimization, the systems firstly equilibrated in NVT ensemble carried out for 0.5 ns. Subsequently, system equilibration was continued in NPT ensemble for an additional 0.5 ns. During both steps, the position of atoms in the complex (proteins, Zn +2 and Cl −1 ions) was restrained using a harmonic potential with spring constant k = 1 kcal/(molÅ 2 ). Production runs were then performed in three replicates of each system for 50 ns. During the production runs, all restraints on the protein were turned off, while dummy bonds between Zn +2 and Cl −1 ions and their adjunct atoms within radius of 3Å were kept intact. The binding free energy for all sets of ligand-receptor complexes was calculated with Molec- Root Mean Squared Deviation (RMSDs), Root Mean Squared Fluctuation (RMSFs), and the distances between RBD and ACE2, H1 and H2 were calculated by tcl scripts taking advantage of VMD. 34 RMSD of each system was calculated by considering the backbone atoms (C α , C, and N). RMSF and the distance among the geometric centers of domains were calculated for C α atoms. All trajectories were fitted to the starting conformation to present the conformational changes during simulation time. All the plots were generated by RMSF plots are also consistent to these observations (Figures 4,5) and show that the most dramatic increase of fluctuations occurs in residues 430 to 450 of RBD in model I. While, models II and III and the 0 present similar fluctuation patterns (Figure 4) . Two residues (GLY446 and Tyr449) within this region are known to interact with the ACE2 directly. 38 These results are interesting as we know which due to the experimental findings, the O-glycans of respiratory airways are often elongated oligosaccharides. 23 Detailed investigations show that decreased flexibility is more pronounced for RBD ( Figure 6 ), while ACE2 average RMSD plots present a noticeable overlap among all systems ( Figure 7 .A-C). ACE2 extracellular domain is a sizable receptor with about 600 amino acids; hence, it is expected that the overall RMSD of receptor would not change by the O-glycosylation of The decreased fluctuations of O-glycosylated models II and III, does not necessarily prove stronger RBD-ACE2 interaction. However, calculating the distance between RBD-ACE2, RBD-H1 and RBD-H2 could provide hints on this interaction. Distribution of the RBD-ACE2 distance values shows a similar pattern (peaks at 49.5Å) in models I and III simulations (Figure 9.A) . While, in model 0 simulations, RBD and ACE2 are by less than 1Å closer (Figure 9 .A). The distance fluctuation between RBD and ACE2 in model II is more altering. In addition to the ACE2-RBD, distances between RBD, H1, and H2 of ACE2 were also measured (Figures 9.B and 9 .C). Plots show that O-glycosylation always leads to a decrease between the RBD and the two helices (Figures 9.B and 9 .C). This decrease is more significant in H2-RBD distance for all O-glycosylated models (Figure 9 .C). While, H1-RBD distance distribution only presents a decrease in the most elongated attached O-glycan model (Figure 9 .B). These observations suggest that RBD-ACE2 binding should be stronger at the direct interface upon O-glycosylation with oligosaccharides. Figure 9 : (A) PDF of RBD to ACE2 averaged distance distribution with a histogram and maximum likelihood gaussian distribution fit: calculated from all replicate of each system and are represented in black, lime, orange and blue for models 0-III respectively. (B) PDF of RBD to H1 averaged distance distribution with a histogram and maximum likelihood gaussian distribution fit: calculated from all simulations of each system and represented in black, lime, orange and blue for models 0-III respectively. (C) PDF of RBD to H2 averaged distance distribution with a histogram and maximum likelihood gaussian distribution fit: calculated from all simulations of each system and represented in black, lime, orange and blue for models 0-III respectively. Sampling were done from the last 30 ns of simulations. The binding free energy between the RBD and ACE2 also shows that the interaction is more favorable upon O-glycosylation in models II and III with longer attached glycans( Figure 10 ). The binding free energies between RBD-ACE2, calculated with the MMPBSA method, For MMPBSA binding energy calculation ligand-receptor complex is first calculated in the gas state and then in solvated state. The overall relative binding free energy is the sum of those two ∆Gs (Eq.1). Each ∆G can be decomposed into the contribution of different interactions and expressed in: 42 Where ∆G mm , -T∆S, ∆G P B and ∆G SA are the ensemble-averaged protein-ligand interactions, entropy contributions, electrostatic, and nonpolar solvation energies, respectively. For calculating the entropic part of the binding energy, Interaction Entropy (IE) method 43 was used: where ∆E int pl represents the fluctuation of protein-ligand interaction energy around the average energy and calculated as follow: 43 where ∆E int pl represents the average of protein-ligand interaction energy. Supplementary Tables Table 1: N-Glycan composition for ACE2 and RBD The proximal origin of SARS-CoV-2 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor The SARS-CoV-2 exerts a distinctive strategy for interacting with the ACE2 human receptor Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV) Hilgenfeld, R. pH-dependent Conformational Flexibility of the SARS-CoV Main Proteinase (Mpro) Dimer: Molecular Dynamics Simulations and Multiple X-ray Structure Analyses Investigation of the effect of temperature on the structure of SARS-Cov-2 Spike Protein by Molecular Dynamics Simulations A systematic approach to protein glycosylation analysis: a path through the maze Deducing the N-and Oglycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor Post-translational modifications of coronavirus proteins: roles and function Glycosylation of the viral attachment protein of avian coronavirus is essential for host cell and receptor binding Glycoinformatics approach for identifying target positions to inhibit initial binding of SARS-CoV-2 S1 protein to the host cell Exploitation of glycosylation in enveloped virus pathobiology O-linked protein glycosylation structure and function An Overview on Glyco-Macrocycles: Potential New Lead and their Future in Medicinal Chemistry Mucins: the frontline defence of the lung The carbohydrate diversity of human respiratory mucins: a protection of the underlying mucosa SARS-CoV-2 and Diabetes: New Challenges for the Disease GLYCAM06: a generalizable biomolecular force field A systematic approach to protein glycosylation analysis: a path through the maze Comparison of simple potential functions for simulating liquid water Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. The journal of physical chemistry B CHARMM36m: an improved force field for folded and intrinsically disordered proteins Scalable molecular dynamics with NAMD Particle mesh Ewald: An N log (N) method for Ewald sums in large systems CaFE: a tool for binding affinity prediction using end-point free energy methods Electrostatics of nanosystems: application to microtubules and the ribosome VMD -Visual Molecular Dynamics Matplotlib: A 2D graphics environment Python 3 Reference Manual ; CreateSpace The PyMOL Molecular Graphics System Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor The impact of interior dielectric constant and entropic change on HIV-1 complex binding free energy prediction Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations Molecular dynamics investigation on a series of HIV protease inhibitors: assessing the performance of MM-PBSA and MM-GBSA approaches The MM/PBSA and MM/GBSA methods to estimate ligandbinding affinities Interaction entropy: a new paradigm for highly efficient and reliable computation of protein-ligand binding free energy We are grateful to the HPC of SUT to provide the computational resources of this study.We are also thankful to H.Rajabi-Maham, H.Mobasheri, R.S.Haltiwanger and ,R.J.Woods for their very useful suggestions.